Table 3.
Cox proportional hazards analysis of failure-free survival in the study population.
| Variables | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | p value | HR (95% CI) | p value | |
| Age (years) | 0.984 (0.956–1.012) | 0.255 | – | – |
| ECOG PS | 0.603 | – | ||
| 0 | 1 | – | ||
| >0 | 1.188 (0.621–2.269) | – | ||
| PSA (ng/mL) | 1.001 (1.000–1.001) | 0.054 | 1 (1.000–1.001) | 0.443 |
| Gleason score | 0.068 | 0.193 | ||
| <8 | 1 | 1 | ||
| ≥8 | 1.597 (0.965–2.642) | 1.411 (0.840–2.369) | ||
| T Stage | 0.006 | 0.026 | ||
| <3 | 1 | 1 | ||
| ≥3 | 2.127 (1.243–3.637) | 1.881 (1.078–3.283) | ||
| N Stage | 0.288 | 0.859 | ||
| 0 | 1 | 1 | ||
| 1 | 1.300 (0.801–2.112) | 1.048 (0.626–1.753) | ||
| Visceral metastases | 0.945 | 0.463 | ||
| 0 | 1 | 1 | ||
| 1 | 1.025 (0.507–2.027) | 0.757 (0.359–1.594) | ||
| Metastatic burden | 0.046 | 0.046 | ||
| Low | 1 | 1 | ||
| High | 1.657 (1.009–2.722) | 1.712 (1.010–2.903) | ||
| Cryoablation | 0.505 (0.308–0.830) | 0.007 | 0.542 (0.329–0.893) | 0.016 |
ECOG PS Eastern Cooperative Oncology Group Performance Status, PSA prostate-specific antigen, HR hazard ratio, CI confidence interval.